Detalles de la búsqueda
1.
Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.
Support Care Cancer;
32(6): 347, 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38743147
2.
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.
Age Ageing;
53(2)2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346934
3.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother;
72(1): 91-99, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35729418
4.
Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
Cancer Immunol Immunother;
71(3): 719-726, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34378081
5.
Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
Lung;
200(1): 95-105, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35141799
6.
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Future Oncol;
17(23): 3007-3016, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156285
7.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol;
21(9): 1224-1233, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32888454
8.
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.
Future Oncol;
16(16): 1115-1124, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32352321
9.
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017).
Future Oncol;
16(4): 5-10, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31894704
10.
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
BMC Cancer;
19(1): 1237, 2019 Dec 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31856742
11.
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.
Future Oncol;
15(14): 1551-1563, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30852916
12.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Lancet Oncol;
19(4): 521-536, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545095
13.
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Eur Respir J;
52(4)2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262574
14.
Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).
Oncology;
94(1): 55-64, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29065416
15.
Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.
Oncology;
95(6): 337-343, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30278447
16.
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
BMC Cancer;
18(1): 1013, 2018 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30348130
17.
Association between lung cancer somatic mutations and occupational exposure in never-smokers.
Eur Respir J;
50(4)2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29074543
18.
PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION.
Int J Technol Assess Health Care;
33(6): 609-619, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29081308
19.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Lancet Oncol;
17(2): 212-223, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26727163
20.
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply.
Lancet Oncol;
21(12): e546, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33271103